^
CANCER:

Gastrointestinal Cancer

MSI-H/dMMR
CRC
nivolumab + ipilimumab
Sensitive: A1 - Approval
J Clin Oncol - 1 week
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
FLOT
Sensitive: C3 – Early Trials
BMC Cancer - 1 week
MSI-H/dMMR
Gastric Cancer
FLOT
Sensitive: C3 – Early Trials
BMC Cancer - 1 week
PIK3CA H1047R
HCC
palbociclib + alpelisib
Sensitive: D – Preclinical
Cell Death Dis - 1 week
PIK3CA H1047R
HCC
alpelisib + TAK-228
Sensitive: D – Preclinical
Cell Death Dis - 1 week
PIK3CA E545K
HCC
alpelisib
Sensitive: D – Preclinical
Cell Death Dis - 1 week
PIK3CA H1047R
HCC
alpelisib
Resistant: D – Preclinical
Cell Death Dis - 1 week
MSI-H/dMMR
Gastric Cancer
dostarlimab
Sensitive: A2 - Guideline
NCCN - 2 weeks
HER-2 positive
Gastric Cancer
ARX788
Sensitive: C3 – Early Trials
Ambrx Press Release - 2 weeks
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
ARX788
Sensitive: C3 – Early Trials
Ambrx Press Release - 2 weeks
KRAS G12C
CRC
bevacizumab
Resistant: C3 – Early Trials
Frontiers - 2 weeks
No biomarker
HCC
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 3 weeks
FGFR2 rearrangement
Cholangiocarcinoma
TAS 120
Sensitive: B - Late Trials
Cancer Discov - 3 weeks
FGFR2 fusion
Cholangiocarcinoma
TAS 120
Sensitive: B - Late Trials
Cancer Discov - 3 weeks
No biomarker
Biliary Tract Cancer
fosgemcitabine palabenamide
Sensitive: B - Late Trials
NuCana Press Release - 3 weeks
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
JAMA Oncol - 3 weeks
BRAF V600E
CRC
cetuximab + encorafenib
Sensitive: A1 - Approval
FDA - 3 weeks
miR-7-5p overexpression
CRC
bevacizumab
Resistant: C3 – Early Trials
Dovepress - 3 weeks
TSPAN6 positive
CRC
cetuximab
Sensitive: C3 – Early Trials
PNAS - 3 weeks
miR-143-3p overexpression
CRC
bevacizumab
Sensitive: C3 – Early Trials
Dovepress - 3 weeks
miR-10a-5p overexpression
CRC
bevacizumab
Resistant: C3 – Early Trials
Dovepress - 3 weeks
HRD
Pancreatic Cancer
ABT-888
Resistant: C4 – Case Studies
Clin Cancer Res - 3 weeks
HER-2 positive
Gastric Cancer
trastuzumab
Sensitive: A2 - Guideline
J Gastrointest Cancer - 4 weeks
FGFR2 amplification
Gastric Cancer
TAS 120
Sensitive: C2 – Inclusion Criteria
Cancer Discov - 4 weeks
FGFR3-TACC3 fusion
Gastric Cancer
TAS 120
Sensitive: C3 – Early Trials
Cancer Discov - 4 weeks
FGFR2-POC1B fusion
Cholangiocarcinoma
TAS 120
Sensitive: C4 – Case Studies
Cancer Discov - 4 weeks
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
HCC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
TPF
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
BRAF V600E
CRC
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
No biomarker
Colon Cancer
capecitabine
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
FOLFIRI
Sensitive: A1 - Approval
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
No biomarker
CRC
bevacizumab
Sensitive: A1 - Approval
HER-2 Negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Zirabev (bevacizumab biosimilar)
Resistant: A1 - Approval
No biomarker
CRC
trifluridine/tipiracil
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine/tipiracil
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
trifluridine/tipiracil
Sensitive: A1 - Approval
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
ramucirumab
Sensitive: A1 - Approval
No biomarker
HCC
cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
CRC
ziv-aflibercept IV
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
capecitabine
Sensitive: A1 - Approval
No biomarker
CRC
capecitabine
Sensitive: A1 - Approval
No biomarker
Pancreatic Cancer
erlotinib
Sensitive: A1 - Approval
EGFR expression
CRC
cetuximab
Sensitive: A1 - Approval
KRAS Q61
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
CRC
ramucirumab
Sensitive: A1 - Approval
No biomarker
CRC
panitumumab
Sensitive: A1 - Approval
KRAS A146
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
irinotecan
Sensitive: A1 - Approval
No biomarker
Colon Cancer
irinotecan
Sensitive: A1 - Approval
No biomarker
HCC
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
AFP elevation
HCC
ramucirumab
Sensitive: A1 - Approval
No biomarker
HCC
regorafenib
Sensitive: A1 - Approval
No biomarker
HCC
lenvatinib
Sensitive: A1 - Approval
No biomarker
HCC
sorafenib
Sensitive: A1 - Approval
KRAS G13
CRC
cetuximab
Resistant: A1 - Approval
KRAS G12
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
CRC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
nivolumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
No biomarker
CRC
regorafenib
Sensitive: A1 - Approval
KRAS K117
CRC
cetuximab
Resistant: A1 - Approval
KRAS A59
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
HCC
nivolumab + ipilimumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
KRAS G12S
CRC
panitumumab
Resistant: A1 - Approval
NRAS Q61
CRC
cetuximab
Resistant: A1 - Approval
NRAS Q61
CRC
panitumumab
Resistant: A1 - Approval
NRAS G13
CRC
panitumumab
Resistant: A1 - Approval
NRAS G13
CRC
cetuximab
Resistant: A1 - Approval
NRAS G12
CRC
panitumumab
Resistant: A1 - Approval
NRAS G12
CRC
cetuximab
Resistant: A1 - Approval
NRAS A146
CRC
cetuximab
Resistant: A1 - Approval
NRAS A146
CRC
panitumumab
Resistant: A1 - Approval
KRAS G13
CRC
panitumumab
Resistant: A1 - Approval
KRAS G61
CRC
panitumumab
Resistant: A1 - Approval